Skip to main content

Table 1 Demographic and clinical baseline characteristics according to treatment group

From: Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study

 

Active Surveillance (n = 99)

Radical prostatectomy (n = 99)

External-beam radiotherapy (n = 99)

Brachytherapy (n = 99)

p-value

Risk group*

 Low risk

74 (74.7%)

74 (74.7%)

74 (74.7%)

74 (74.7%)

1.000

 Intermediate risk

25 (25.3%)

25 (25.3%)

25 (25.3%)

25 (25.3%)

 

Age at HRQoL survey, mean (SD), years

70.6 (5.4)

68.2 (5.4)

73.2 (5.3)

71.9 (5.0)

0.065

Elapsed time from treatment selection to HRQoL survey, years

 Mean (SD)

2.6 (1.5)

3.1 (1.9)

2.8 (1.9)

2.9 (1.7)

0.434

 Median [IQR]

2.4 [1.4–3.6]

3.1 [1.0–4.1]

2.0 [1.0–4.1]

3.0 [1.0–4.1]

 

 Minimum - Maximum

0.53–7.32

0.45–8.32

0.46–8.32

0.48–7.06

 

PSA, mean (SD), ng/ml

6.8 (2.9)

7.3 (2.8)

7.7 (3.0)

7.6 (2.6)

0.087

 PSA ≤ 10

84 (84.8%)

88 (89.8%)

84 (84.8%)

85 (85.9%)

0.709

 PSA > 10

15 (15.2%)

10 (10.2%)

15 (15.2%)

14 (14.1%)

 

Gleason score

 2–5

0

12 (12.1%)

30 (30.3%)

28 (28.2%)

< 0.001a,b,c

 6

90 (90.9%)

72 (72.7%)

53 (53.5%)

64 (64.6%)

 

 7 (3 + 4)

9 (9.1%)

15 (15.2%)

16 (16.2%)

7 (7.1%)

 

Clinical stage

 T1a-T1c

78 (78.8%)

71 (71.7%)

68 (68.7%)

80 (80.3%)

0.157

 T2a-T2b

21 (21.2%)

28 (28.3%)

31 (31.3%)

19 (19.2%)

 

Comorbidities

 Osteoarthritis or Rheumatism

 

31 (43.1%)

44 (48.9%)

40 (50.6%)

0.623

 High blood pressure

 

26 (36.1%)

33 (36.7%)

33 (41.8%)

0.723

 Depression or Mental disorders

 

13 (18.1%)

12 (13.3%)

17 (21.5%)

0.370

 Chronic respiratory diseases

 

7 (9.7%)

17 (18.9%)

16 (20.3%)

0.168

 Ischemic heart disease

 

6 (8.3%)

16 (17.8%)

11 (13.9%)

0.220

 Diabetes mellitus

 

8 (11.1%)

13 (14.4%)

10 (12.7%)

0.818

 Stroke

 

2 (2.8%)

3 (3.3%)

4 (5.1%)

0.737

  1. *According to d’Amico prostate cancer risk classification
  2. a: active surveillance vs radical prostatectomy; b: active surveillance vs external-beam radiotherapy; c: active surveillance vs brachytherapy